Alpha Cognition completed its second quarter of ZUNVEYL® commercialization in 3Q25, with launch momentum accelerating across the U.S. long-term care (LTC) channel. Pharmacy orders grew 102% sequentially, supported by record prescription volumes each month and expanding reach into more than 600 nursing homes, while the prescriber base surpassed 500 clinicians. The LTC-focused field team continued reinforce ZUNVEYL’s differentiated cognitive and behavioral profile alongside a favorable tolerability signal in real-world use. Management’s long-term care call strategy remains central to the launch, with growing evidence of durable adoption and repeat ordering behavior as the brand becomes more embedded in high-volume facilities.